A broad-spectrum SARS-CoV-2 RBD vaccine with selected high-impact mutations and novel adjuvant induces durable T cell response and broad protection in mice
Frontiers in Cellular and Infection Microbiology · 2026
DOI: 10.3389/fcimb.2025.1690554 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2026. Verfasst von Xianying Chen und 19 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Virology and Biosafety, Animal Bio-safety Level III Laboratory, College of Life Sciences and Frontier Science Center for Immu…. Hauptthemen laut MEDLINE: SARS-CoV-2, T-Lymphocytes, COVID-19 Vaccines, Spike Glycoprotein, Coronavirus. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
The emergence of new SARS-CoV-2 variants with immune evasion capabilities underscores the importance of developing a broad-spectrum and effective vaccine. The receptor binding domain (RBD) of the Spike protein has been widely utilized in vaccine due to its high immunogenicity. However, the Spike protein, particularly the RBD region, exhibits significant variability in the evolution of SARS-CoV-2, leading to viral immune evasion and reduced vaccine effectiveness.
Methods
A broad-spectrum antigen (M5-RBD) was developed via mutation patching, incorporating key high-impact mutation sites (K417T, L452R, T478K, E484K, N501Y). Additionally, extra mutations (N440K or G446S) were introduced into M5-RBD to evaluate their impact on immune response. M5-RBD was further combined with a novel CpG adjuvant HP007 for immunization.
Results
M5-RBD elicited high titers of broad-spectrum neutralizing antibodies against SARS-CoV-2 wild-type and various variants (Delta, Omicron BA.1, BA.2, BA.2.75, BA.5, BF.7, BQ.1.1, XBB, EG.5, JN.1, KP.3 strains). Introduction of N440K or G446S significantly diminished the immune response to viral strains. When combined with HP007 adjuvant, M5-RBD induced efficient and durable T cell responses, providing protection to K18-hACE2 KI mice against lethal infections with both wild-type and Omicron BA.2 strains.
Discussion
Rationally designed with key high-impact mutation sites, M5-RBD effectively overcomes SARS-CoV-2 variant immune evasion and elicits broad-spectrum neutralizing antibodies. The combination with HP007 adjuvant enhances immune protection, providing a promising strategy for the development of next-generation COVID-19 vaccines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Virology and Biosafety, Animal Bio-safety Level III Laboratory, College of Life Sciences and Frontier Science Center for Immunology and Metabolism, Wuhan University, Wuhan, China.
- Jiangsu Taipure Biopharmaceuticals Co., Ltd., Taizhou, China.
Zitieren
APA
Chen, X., Zhang, Y., Yang, S., Chen, Y., Qian, S., Zhang, Z., Liu, Q., Ma, C., Yu, W., Feng, J., Liu, J., Guo, M., Huang, Z., Wang, X., Chen, J., Zhao, H., Yan, H., Lan, K., Chen, Y., & Zhou, L. (2026). A broad-spectrum SARS-CoV-2 RBD vaccine with selected high-impact mutations and novel adjuvant induces durable T cell response and broad protection in mice. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2025.1690554
Vancouver
Chen X, Zhang Y, Yang S, Chen Y, Qian S, Zhang Z, et al. A broad-spectrum SARS-CoV-2 RBD vaccine with selected high-impact mutations and novel adjuvant induces durable T cell response and broad protection in mice. Frontiers in Cellular and Infection Microbiology. 2026. doi:10.3389/fcimb.2025.1690554
BibTeX
@article{Chen2026,
author = {Chen, Xianying and Zhang, Yuzhen and Yang, Shimin and Chen, Yan and Qian, Shengnan and Zhang, Zhen and Liu, Qianyun and Ma, Chengbao and Yu, Weiyi and Feng, Jiangpeng and Liu, Jiejie and Guo, Ming and Huang, Zhixiang and Wang, Xin and Chen, Jie and Zhao, Haiyan and Yan, Huan and Lan, Ke and Chen, Yu and Zhou, Li},
title = {A broad-spectrum SARS-CoV-2 RBD vaccine with selected high-impact mutations and novel adjuvant induces durable T cell response and broad protection in mice},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2026},
doi = {10.3389/fcimb.2025.1690554}
}
EUVIMED